Extracorporeal Photopheresis - An Overview

被引:79
|
作者
Cho, Ara [1 ]
Jantschitsch, Christian [1 ]
Knobler, Robert [1 ]
机构
[1] Med Univ Wien, Dept Dermatol, Vienna, Austria
关键词
ECP; ultraviolet A; CTCL; GVHD; scleroderma; solid organ transplantation; VERSUS-HOST-DISEASE; T-CELL LYMPHOMA; HEART-TRANSPLANT REJECTION; SEVERE ATOPIC-DERMATITIS; BRONCHIOLITIS OBLITERANS SYNDROME; CONSENSUS DEVELOPMENT PROJECT; SYSTEMIC-SCLEROSIS; CLINICAL-TRIALS; DENDRITIC CELLS; CROHNS-DISEASE;
D O I
10.3389/fmed.2018.00236
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after receiving FDA approval for the palliative treatment of the Sezary Syndrome variant of cutaneous T-cell lymphoma (CTCL) in 1988. After the first positive experiences with CTCL, additional indications have been successfully explored including areas such as graft-vs.-host disease (GVHD), scleroderma, and solid organ transplantation. The mechanism of action is still not fully resolved, but important steps in understanding ECP in recent years have been very informative. Originally, the primary hypothesis stated that psoralen and ultraviolet A (UVA) in combination induce apoptosis in the treated immune cells. This view shifted in favor of dendritic cell initiation, modification of the cytokine profile and stimulation of several T-cell lineages, in particular regulatory T-cells. A number of ECP guidelines have been produced to optimize treatment regimens in the clinical context. In CTCL, enough evidence is available for the use of ECP as a first line treatment for Sezary Syndrome (SS), but also as a second line or rescue treatment in therapy-refractory forms of mycosis fungoides (MF). ECP in the treatment of acute and chronic GVHD has shown promising results as second line therapy in steroid-refractory presentations. In solid organ transplantation, ECP has been used to increase tissue tolerance and decrease infections with opportunistic pathogens, attributed to the use of high doses of immunosuppressive medication. Infection with cytomegalovirus (CMV) remains a limiting factor affecting survival in solid organ transplantation and the role of ECP will be discussed in this review. A trend toward prophylactic use of ECP can be observed and may further contribute to improve the outcome in many patients. To further deepen our knowledge of ECP and thus facilitate its use in patients that potentially benefit most from it, future prospective randomized trials are urgently needed in this rapidly growing field. The aim of this review is to (1) introduce the method, (2) give an overview where ECP has shown promising effects and has become an essential part of treatment protocols, and (3) to give recommendations on how to proceed in numerous indications.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Extracorporeal photopheresis in conditions of autoimmunity
    Webb, Christopher
    TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (02)
  • [22] Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sezary Syndrome
    Zic, John A.
    DERMATOLOGIC CLINICS, 2015, 33 (04) : 765 - +
  • [23] Extracorporeal Photopheresis: a Review on the Immunological Aspects and Clinical Applications
    Chiesa-Fuxench, Zelma C.
    Gonzalez-Chavez, Jose
    PUERTO RICO HEALTH SCIENCES JOURNAL, 2010, 29 (04) : 337 - 347
  • [24] Extracorporeal photopheresis in pediatric patients: Practical and technical considerations
    DeSimone, Robert A.
    Schwartz, Joseph
    Schneiderman, Jennifer
    JOURNAL OF CLINICAL APHERESIS, 2017, 32 (06) : 543 - 552
  • [25] Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status
    Lozano, Miquel
    Charry, Paola
    de Pablo-Miro, Mar
    Salas, Maria-Queralt
    Martinez, Carmen
    Suarez-Lledo, Maria
    Fernandez-Aviles, Francesc
    Rovira, Montserrat
    Cid, Joan
    BONE MARROW TRANSPLANTATION, 2024, 59 (09) : 1209 - 1214
  • [26] Extracorporeal photopheresis as an immunomodulatory agent: Haematocrit-dependent effects on natural killer cells
    Becherucci, V.
    Allegro, E.
    Brugnolo, F.
    Piccini, L.
    Gori, V.
    Bisin, S.
    Bindi, B.
    Ceccantini, R.
    Pavan, P.
    Cunial, V.
    Gentile, F.
    Ermini, S.
    Bambi, F.
    JOURNAL OF CLINICAL APHERESIS, 2017, 32 (04) : 257 - 265
  • [27] Extracorporeal Photopheresis: How, When, and Why
    Ward, David M.
    JOURNAL OF CLINICAL APHERESIS, 2011, 26 (05) : 276 - 285
  • [28] Extracorporeal photopheresis for the treatment of autoimmune diseases
    Adamski, Jill
    Kinard, Theresa
    Ipe, Tina
    Cooling, Laura
    TRANSFUSION AND APHERESIS SCIENCE, 2015, 52 (02) : 171 - 182
  • [29] Use of Extracorporeal Photopheresis in Scleroderma: A Review
    Du, Amy X.
    Osman, Mohamed
    Gniadecki, Robert
    DERMATOLOGY, 2020, 236 (02) : 105 - 110
  • [30] Extracorporeal photopheresis after heart transplantation
    Barten, Markus J.
    Dieterlen, Maja-Theresa
    IMMUNOTHERAPY, 2014, 6 (08) : 927 - 944